Stonehage Fleming Financial Services Holdings Ltd Makes New $530,000 Investment in Illumina, Inc. (NASDAQ:ILMN)

Stonehage Fleming Financial Services Holdings Ltd bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,968 shares of the life sciences company’s stock, valued at approximately $530,000.

Several other large investors have also added to or reduced their stakes in ILMN. Versant Capital Management Inc boosted its holdings in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares in the last quarter. TD Private Client Wealth LLC grew its holdings in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the period. Massmutual Trust Co. FSB ADV increased its stake in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Private Trust Co. NA raised its holdings in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares during the period. Finally, Focused Wealth Management Inc bought a new position in shares of Illumina during the 3rd quarter worth about $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Leerink Partners upped their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Piper Sandler reduced their price target on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Morgan Stanley lowered their price objective on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Barclays lifted their price objective on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Finally, Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and dropped their price target for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Stock Up 1.1 %

NASDAQ:ILMN opened at $136.22 on Monday. The business has a fifty day simple moving average of $138.93 and a two-hundred day simple moving average of $134.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.33 EPS. On average, analysts anticipate that Illumina, Inc. will post 4.13 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.